Potent and selective inhibitors of human immunodeficiency virus protease structurally related to L-694,746

Antiviral Chemistry and Chemotherapy

Volumn 9, Issue 4, 1998, Pages 303-309

  Franchetti, P ^a   Perlini, P ^a   Abu Sheikha, G ^a   Cappellacci, L ^a   Grifantini, M ^a   Loi, A G ^b   De Montis, A ^b   Pani, A ^b   Marongiu, M E ^b   La Colla, P ^b  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Enzyme inhibitors; HIV; HIV 1 protease

Indexed keywords

ANTIGEN P24; L 689502; N [2 HYDROXY 1 INDANYL] 5 [(TERT BUTYLOXYCARBONYL)AMINO] 4 HYDROXY 6 PHENYL 2 [[4 (CARBOXYMETHOXY)PHENYL]METHYL]HEXANAMIDE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

AMIDES; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CELL LINE; ENZYME INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; MOLECULAR STRUCTURE; MORPHOLINES; PEPTIDES;

EID: 0031846506     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Balani SK, Pitzenberger SM, Schwartz MS, Ramjit HG & Thompson WJ (1995) Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors. Drug Metabolism and Disposition 23:185-189.
2. Connelly MC, Robbins BL & Fridland A (1993) Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyljcytosine (HPMPC) in Vero cells. Biochemical Pharmacology 46:1053-1057.
3. Darke PL, Nutt RF, Brady SF, Garsky VM, Ciccarone TM, Leu CT, Lumma PK, Freidinger RM, Veber DF & Sigal I (1988) HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochemical and Biophysical Research Communications 156:297-303.
4. De Clercq E (1997) In search of a selective antiviral chemotherapy. Clinical Microbiology Reviews 10:674-693.
5. De Lombaert S, Erion MD, Tan J, Blanchard L, El-Chehabi L, Ghai RD, Sakane Y, Berry C & Trapani AJ (1994) N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors. Journal of Medicinal Chemistry 37:498-511.
6. De Lombaert S, Blanchard L, Tan J, Sakane Y, Berry C & Ghai RD (1995) Non-peptidic inhibitors of neutral endopeptidase 24.11. 1. Discovery and optimization of potency. Bioorganic & Medicinal Chemistry Letters 5:145-150.
7. Dorsey BD, Levin RB, McDaniel SL, Vacca JP, Guare JP, Darke PL, Zugay JA, Emini EA, Schleif WA, Quintero JC, Lin JH, Chen I-W, Holloway MK, Fitzgerald PMD, Axel MG, Ostovic D, Anderson PS & Huff JR (1994) L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. Journal of Medicinal Chemistry 37:3443-3451.
8. Giannousis PP & Bartlett PA (1987) Phosphorus amino acid analogues as inhibitors of leucine aminopeptidase. Journal of Medicinal Chemistry 30:1603-1609.
9. Huff J (1991) HIV protease: a novel chemotherapeutic target for AIDS. Journal of Medicinal Chemistry 34:2305-2314.
10. Kaldor SW, Kalish VJ, Davies JF II, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS & Talock JH (1997) Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. Journal of Medicinal Chemistry 40:3979-3985.
11. Kempf DJ, Marsh KC, Denissen J, McDonald E, Vasavanonda S, Flentge C, Green BG, Fino L, Park C, Kong X, Wideburg NE, Saldivar A, Ruiz L, Kati WM, Sham HL, Robins T, Stewart KD, Plattner JJ, Leonard J & Norbeck D (1995) ABT-538 is a potent inhibitor of human immunodeficiency virus protease with high bioavailability in humans. Proceedings of the National Academy of Sciences, USA 92:2484-2488.
12. Krecmerova M, Hrebabecky H & Holy A (1990) Synthesis of 5′-O-phosphonomethyl derivatives of pyrimidine 2′-deoxynucleosides. Collection of Czechoslovak Chemical Communications 55:2521-2536.
13. Lingham RB, Arison BH, Colwell LF, Hsu A, Dezeny G, Thompson WJ, Garrity GM, Gagliardi MM, Hartner FW, Darke PL, Balani SK, Pitzenberger SM, Murphy JS, Ramijt HG, Inamine ES & Treiber LR (1991) HIV-1 protease inhibitory activity of L-694,746, a novel metabolite of L-689,502. Biochemical and Biophysical Research Communications 181:1456-1461.
14. Martin JL, Brown CE, Mathews-Davis N & Reardon JE (1994) Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrobial Agents & Chemotherapy 38:2743-2749.
15. Navia MA, Fitzgerald, McKeever BM, Leu C-T, Heimbach JC, Herber WK, Sigal IS, Darke PL & Sringer JP (1989) Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337:615-620.
16. Palù G, Stefanelli S, Rassu M, Parolin C, Balzarini J & De Clercq E (1991) Cellular uptake of phosphonylmethoxyalkylpurine derivatives. Antiviral Research 16:115-119.
17. Parker WB & Cheng YC (1994) Mitochondrial toxicity of antiviral nucleoside analogs. Journal of NIH Research 6:57-61.
18. Parkes KEB, Bushnell DJ, Crackett PH, Dunsdon SJ, Freeman AC, Gunn MP, Hopkins RA, Lambert RW, Martin JA, Merrett JH, Redshaw S, Spurden WC & Thomas GJ (1994) Studies toward the large-scale synthesis of the HIV proteinase inhibitor Ro 31-8959. Journal of Organic Chemistry 59:3656-3664.
19. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J & De Clercq E (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods 20:309-321.
20. Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB, Galpin SA, Handa BK, KayJ, Kröhn A, Lambert RW, Merrett JH, Mills JS, Parkes KEB, Redshaw S, Ritchie AJ, Taylor DL, Thomas GJ & Machin PJ (1990) Rational design of peptide-based proteinase inhibitors. Science 248:358-361.
21. Shirasada T, Kavlick MF, Veno T, Gao W-Y, Kojima E, Alcaide ML, Chokekijchai S, Roy BM, Arnold E, Yarchoan R & Mitsuya H (1995) Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxy nucleosides in patients receiving therapy with dideoxy nucleosides. Proceedings of the National Academy of Sciences, USA 92:2398-2402.
22. Thompson W, Fitzgerald PMD, Holloway MK, Emini EA, Darke PL, McKeever BM, Schleif WA, Quintero JC, Zugay JA, Tucker TJ, Schwering JE, Homnick CF, Nunberg J, Springer JP & Huff JR (1992) Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the Pl or P1′ phenyl substituents: X-ray crystal structure assisted design. Journal of Medicinal Chemistry 35:1685-1701.
23. Uchida M, Komatsu M, Morita S, Kanbe T & Nakagawa K (1989) Studies on gastric antiulcer active agents. II. Synthesis of tetrazole alkanamides and related compounds. Chemical Pharmaceutical Bulletin 37:322-326.
24. Yu K-L, Bronson JJ, Yang H, Patik A, Alam M, Brankovan V, Datema R, Hitchcock MJM & Martin JC (1992) Synthesis and antiviral activity of methyl derivatives of 9-[2(phospho-nomethoxy)ethyl]guanine. Journal of Medicinal Chemistry 35:2958-2969.